1.Previous
3.Next

of participants at a faster rate, in comparison to a single-center trial, putting to use the sources of multiple institutions. This is crucial when the anticipated benefit from a treatment will be relatively small, or an expected outcome is likely to be uncommon, making a larger sample size necessary. Therefore, studies on preventive measures and therapies tend to be designed as multicenter trials. In studying novel pharmaceuticals, Phase III trials, which compare the

1.Previous
3.Next